Cytrellis Announces Jason Richey as President and Chief Executive Officer

News provided by

Jun 01, 2022, 08:00 ET

WOBURN, Mass., June 1, 2022 /PRNewswire/ -- Cytrellis Biosystems Inc., a medical technology company dedicated to the development and commercialization of first-in-class aesthetic devices which emphasize safety, efficacy, and improved quality of life for patients, today announced that Jason Richey has been named as President and Chief Executive Officer ("CEO").

"We are thrilled to welcome Jason to the Cytrellis leadership team as he brings 25 years of proven experience in the medical device industry. As Cytrellis moves toward the nationwide launch of the ellacor^® System with Micro-Coring™ Technology in the United States, Jason's strength in commercial and operational functions will be invaluable," said John McDonough, Chairman of the Board of Directors at Cytrellis.

Most recently, Jason served as President and Chief Operating Officer ("COO") of Cutera, a leading manufacturer of energy-based aesthetic systems. He was responsible to ensure the company's vision, mission, and corporate values were established and followed to meet or exceed the company's financial plans by implementing processes and oversight that drove significant improvements in global market share, top-line growth, and gross margins.

Prior to Cutera, Jason served a dual executive role as President of North America and President of the Neuromodulation Franchise for LivaNova, PLC, a $4 billion global medical device manufacturer with a presence in more than 100 countries worldwide. He joined LivaNova from Cyberonics, Inc. where he served as the Global Vice President of Sales, Marketing, and Market Access among many other roles. In every leadership role he has held, Jason drove substantial top-line growth and profitability for the corporation. Jason began his medical device career at B. Braun Medical, Inc. and holds a Bachelor of Arts degree in Biology from Indiana University.

"I'm honored to be joining Cytrellis at this pivotal stage of growth for the company," said Jason. "With our novel, disruptive technology and dedicated, talented team, I look forward to solidifying Cytrellis' place in the aesthetic device market as a leader in the industry."

About Cytrellis Biosystems, Inc.

Cytrellis Biosystems, Inc. is a medical technology company whose first product, the ellacor^® System with Micro-Coring™ Technology, is a novel class of aesthetic devices designed to remove sagging skin associated with aging without surgery or scarring, enabling aesthetic practitioners an unprecedented ability to improve age-related changes in skin and restore youthful beauty. Cytrellis is dedicated to working with leading dermatologists and plastic surgeons to develop unique product solutions which emphasize safety, clinical results and improved quality of life. To find out more, please visit us at www.cytrellis.com.

SOURCE Cytrellis Biosystems Inc.